Physician profile
Carey Langley Cano
NPI 1114986809
$16,430.43
in general payments reported to CMS, 2019-2025
24 companies · $5,735 in 2025
The $5,735 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,733 · 2022: $2,109 · 2023: $2,972 · 2024: $3,883 · 2025: $5,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,838 · Consulting Fee: $2,294 · Education: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,838.07 |
| Consulting Fee | $2,294.00 |
| Education | $456.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,694.13 | 2021-2025 | Tremfya |
| Abbvie INC. | $2,453.60 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $1,776.20 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $1,675.86 | 2021-2025 | Dupixent |
| Genzyme Corporation | $1,350.27 | 2021-2025 | |
| Incyte Corporation | $1,280.55 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $1,064.75 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $769.14 | 2021-2025 | Jublia, Cabtreo, Siliq |
| Leo Pharma INC. | $696.05 | 2021-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $567.29 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Lilly USA, LLC | $490.84 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $457.66 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $457.34 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $177.35 | 2022-2025 | |
| Fresenius Kabi USA, LLC | $116.72 | 2023-2024 | Idacio |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $107.71 | 2022-2025 | Nemluvio |
| Vyne Pharmaceuticals INC. | $79.50 | 2021 | |
| Epi Health, LLC | $56.78 | 2021-2022 | |
| Amgen INC. | $42.22 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.83 | 2022 | |
| Organon LLC | $23.25 | 2025 | Vtama |
| Botanix Sb INC | $21.41 | 2025 | Sofdra |
| Almirall LLC | $21.00 | 2021 | |
| Biofrontera INC. | $17.98 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carey Cano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.